The storage (irritative) and voiding (obstructive) symptoms associated with benign prostatic hyperplasia are generally attributed to prostate enlargement and increased prostatic smooth muscle tone mediated by the prevailing a 1 -adrenoceptors in the bladder neck and prostate. This results in obstruction and subsequent secondary changes to the bladder. However, there is growing evidence that many of these symptoms may be due to changes in extraprostatic a 1 -adrenoceptors, possibly a 1D -adrenoceptors. Findings from the VA cooperative trial challenge the current theory that the common side effects associated with these agents are due to vascular action of a 1 -adrenoceptor blockers. Prostate Cancer and Prostatic Diseases (2000) 3, 76±83.
Introduction
Benign prostatic hyperplasia (BPH) is usually a slowly progressive condition, which is associated with bothersome storage (irritative) and voiding (obstructive) symptoms. The voiding symptoms have traditionally been considered to be due to an enlarged prostate impinging on the urethra (the static component) and contraction of prostatic smooth muscle within the stroma (the dynamic component). 1 Storage symptoms may also be related to bladder dysfunction secondary to increased out¯ow resistance.
For years, the accepted consensus suggested that the ef®cacy of a 1 -adrenoceptor blockers in BPH is mediated through the a 1 -adrenoceptors in the prostate smooth muscle and bladder neck, while their side effects, such as asthenia and dizziness, are mediated via a 1 -adrenoceptors within the vasculature. This article describes evidence that suggests that these effects might be mediated, at least in part, via an effect on the central nervous system.
Relationships between lower urinary tract symptoms, prostate enlargement, and obstruction
Connections between lower urinary tract symptoms, prostate enlargement and bladder outlet obstruction are unclear. 2 The severity of lower urinary tract symptoms (LUTS) does not correlate with prostate size or obstruction. 3, 4 Furthermore, many patients continue to experience storage symptoms despite relief of obstruction via prostatectomy. 5 Conversely, Schapiro et al found that a sub-group of men undergoing transurethral resection of the prostate (TURP) had no evidence of obstruction but experienced similar improvements in voiding symptoms as those patients with obstruction who also underwent TURP. 2 Various studies also demonstrate that symptom relief provided by a 1 -adrenoceptor blockers does not correlate with severity of symptoms, prostate size or the presence or absence of obstruction. 6 ± 8 In the VA cooperative trial, patients strati®ed by baseline peak¯ow rate (quartiles: 8. 65 , 8.65 ± 10.75, 10.75 ± 12.45, b 12.45 ml/s) responded equally well to an a 1 -adrenoceptor blocker, and there was no relationship between changes in symptom score and ow rate. 7 Thus, patients with LUTS may or may not have obstruction.
BPH is an imprecise term that does not help predict which patients will respond to treatment. More precise terms include benign prostate enlargement (BPE), bladder outlet obstruction (BOO), and LUTS. As our understanding of the pathophysiology of BPH improves, it should be possible to develop more precise and clinically meaningful de®nitions of BPH.
Pathophysiology of BPH
The causes of prostate growth with advancing age have yet to be con®rmed. The male hormone, testosterone, and its more active metabolite dihydrotestosterone (DHT) control the growth and development of the prostate. DHT stimulation of androgen receptors results in the transcription and translation of growth factors, which have yet to be identi®ed. 9 ± 11 There is also some evidence that sympathetic overactivity may have a smooth muscle hypertrophic effect, although these data are controversial. On the other hand, physically active men have a low frequency of LUTS. 12 Structural changes to the bladder, such as smooth muscle hypertrophy and connective tissue in®ltration, result in detrusor instability in about half to two-thirds of patients with BPH. 13 However, it is unclear whether these changes are due to bladder outlet obstruction. In animal models, eg rats and guinea pigs, urethral obstruction results in secondary changes to the detrusor muscle. 14,15 However, when the urethral obstruction is reversed in rats, there is a subset (20%) that continues to have hyperactive voiding despite a reversal of the bladder hypertrophy. 16 Findings from a study of human autopsies also suggest that these changes are unrelated to obstruction, since there is an increase in connective tissue relative to smooth muscle with age in both men and women. 17 
Adrenergic innervation of lower urinary tract
There is dense adrenergic innervation of the trigonal region, the proximal urethra and the prostate. 18 Although both a 1 -adrenoceptors and a 2 -adrenoceptors are found in the prostate, 19,20 prostatic smooth muscle tone is mediated primarily by a 1 -adrenoceptors. 19, 21, 22 Three high-af®nity a 1 -adrenoceptor subtypes: a 1A , a 1B , and a 1D have been cloned and characterized. 23 A fourth receptor subtype, the a 1L -adrenoceptor with low af®nity for prazosin, has also been pharmacologically de®ned but not fully characterized or cloned. 24 However, it is not clear whether this subtype differs structurally from the a 1A -adrenoceptor or represents a distinct pharmacological site on the a 1A -adrenoceptor. 25, 26 All three high-af®nity receptors are present in the prostate. 27, 28 Quanti®cation of a 1 -adrenoceptor mRNA expression within human prostatic tissue suggests that the distribution of subtypes might differ between normal and hyperplastic prostates. Within normal prostates, the a 1A -adrenoceptor predominates (63%), followed by a 1D -adrenoceptor (31%), and a 1B -adrenoceptor (6%). This predominance of the a 1A -adrenoceptor is more marked in the hyperplasic prostates (a 1A :a 1B :a 1D , 85:1:14). 29 The a 1A -adrenoceptor is preferentially distributed to the stroma, a 1B -adrenoceptor to the epithelium, and a 1D -adrenoceptor to the stroma and blood vessels. 30 Both a 1A -adrenoceptor and a 1L -adrenoceptor subtypes can be demonstrated as pharmacological entities in the human prostatic urethra. 31 ± 33 The number of a 1 -adrenoceptors within the bladder is low, although some investigators have suggested that these receptors are up-regulated in hyperactive detrusor muscle. 34, 35 These data are inconclusive, however, due to technical dif®culties in measuring the extremely low number of receptors.
a a 1 -Adrenoceptors in central and peripheral nervous structures Noradrenaline-containing neurones supply the sympathetic, parasympathetic and somatic nuclei in the lumbosacral spinal cord. 36 Excitatory a 1 -adrenoceptors may be involved in bladder activation via the bulbospinal pathways. Central, facilitatory a 1 -adrenoceptors appear to be involved in the sympathetic and somatic neural control of the cat lower urinary tract. 37, 38 Animal studies have also demonstrated facilitatory a 1 -adrenoceptors on cholinergic neurones in vesical ganglia of the cat 39 and on cholinergic terminals in the rat bladder. 40 Although a 2 -adrenoceptors are the predominant receptor in the spinal cord, a 1a -adrenoceptor, a 1b -adrenoceptor and a 1d -adrenoceptor mRNA are found in the parasympathetic nucleus in the human lumbosacral spinal cord. The a 1d -adrenoceptor subtype predominates over the other a 1 -adrenoceptor subtypes in the sensory and autonomic regions of the spinal cord. 41 a a 1 -Adrenoceptors in the cardiovascular system a 1 -Adrenoceptors regulate blood pressure, regional vascular resistance and venous capacitance. However, the exact subtype mediating these effects is unknown. Although distribution appears to be species and vesseldependent, a 1A -adrenoceptor, a 1B -adrenoceptor, a 1D -adrenoceptor, and a 1L -adrenoceptor subtypes all appear to mediate the contractile response of vascular tissue. 42 ± 44 The human a 1A -adrenoceptor seems to be the predominant a 1 -adrenoceptor subtype in arterial smooth muscle, 45 but this does not necessarily mean that this subtype a a 1 -Adrenoceptor selectivity in BPH treatment R Kirby et al controls systemic blood pressure and orthostasis. One could assume cardiovascular homeostasis depends on all of the multiple subtypes, albeit to varying extents. 45 ± 47 Uroselectivity a 1 -Adrenoceptor blockers were previously thought to relieve symptoms in BPH by inhibiting a 1A -adrenoceptors in the prostatic smooth muscle, while their vascular sideeffects, such as hypotension, were attributed to their inhibition of a 1B -adrenoceptor within the vasculature. However, although there is a correlation between a 1A -adrenoceptor activity and prostatic contraction, 48, 49 the involvement of other prostatic a 1 -adrenoceptors cannot be excluded. 25, 26 Also, since all four subtypes appear to mediate contraction of vascular tissue, cardiovascular homeostasis may depend on multiple subtypes.
There is some in vitro evidence that tamsulosin exhibits a 12-fold higher af®nity for a-adrenoceptors in the prostate than in the aorta, 50 and animal models of urethral and vascular hypertonia suggest that alfuzosin has a higher af®nity for the genitourinary than for the vascular a 1 -adrenoceptors. 51 However, in a direct in vitro comparative study the current a 1 -adrenoceptor blockers (prazosin, doxazosin, terazosin, alfuzosin, and tamsulosin) exhibited little or no selectivity for any of three cloned subtypes. 52 Furthermore, selective a 1A -adrenoceptor antagonists can only be uroselective if the a 1A -adrenoceptor subtype is predominant in the prostate, bladder neck, and urethra, but not in other parts of the body. Since the a 1A -adrenoceptor is ubiquitous, drugs selective for this subtype would not be expected to be uroselective.
Uroselectivity can also be de®ned from a functional or physiological perspective ie agents that increase urinarȳ ow but do not have an effect on blood pressure could be considered to be uroselective. Several animal models, including the spontaneously hypertensive rat (SHR), have been used to investigate the relationship between changes in urethral pressure and blood pressure following the administration of a 1 -adrenoceptor blockers. 51 ± 54 Rec 15/2739 (SB 216469; a selective a 1A -adrenoceptor antagonist) was found to be uroselective while prazosin, terazosin and doxazosin were not. Tamsulosin and alfuzosin exhibited modest or no uroselectivity, depending on the models used. Therefore, these models are not predictive of uroselectivity in humans, since the apparent uroselectivity tends to be species and assay dependent. 55, 56 Also, these models do not include non-cardiovascular side effects, such as drowsiness and dizziness that may be dose-limiting clinically. Uroselectivity might also be related to the distribution of the a 1 -adrenoceptor blocker at the target sites relative to its distribution at the sites of toxicity.
Side effect pro®les of current a a 1 -adrenoceptor blockers
The multicentred, randomized, double-blind placebocontrolled trials of a 1 -adrenoceptor blockers are powered to show differences in ef®cacy but not in safety. Since these agents are generally well tolerated, 57 ± 67 larger sample sizes are required to distinguish differences in their side-effect pro®les. The comparative trial of alfuzosin vs tamsulosin was also underpowered to demonstrate any differences in the side-effect pro®les of the two agents. 68 The incidences of adverse events must be interpreted relative to their effectiveness, since the ef®cacy and tolerability of a 1 -adrenoceptor blockers are both dose dependent.
In individual placebo-controlled trials, between 4 and 16% of men discontinue a 1 -adrenoceptor blockers as result of adverse events. Treatment-related incidences of adverse events associated with terazosin and doxazosin appear to be similar. The available data suggest that retrograde ejaculation and rhinitis are more common with tamsulosin than with terazosin and doxazosin, while dizziness and asthenia are more common with terazosin and doxazosin. However, overall there are no clinically signi®cant differences in their side-effect pro®les. 57 ± 67 Evidence for a central effect of adverse events associated with a a 1 -adrenoceptor blockers Clinical consensus assumes that the common adverse events associated with a 1 -adrenoceptor blockers (eg dizziness and asthenia) are due to vascular events. However, there is compelling evidence from the VA cooperative study that asthenia and dizziness are not due to vascular effects. 69 In the VA cooperative trial, dizziness, asthenia and postural hypotension were signi®cantly more common in the terazosin group than in the placebo group (Table 1) . Orthostatic changes, de®ned as a decrease in systolic blood pressure of more than 20 mmHg between lying and standing, and postural symptoms, de®ned as lightheadedness on standing, were also more common in the terazosin group (P`0.001). When the incidence of adverse events within the terazosin group was analysed by the presence or absence of orthostatic changes, as could be expected, postural symptoms were more common in patients with orthostatic changes than in those without orthostatic changes. However, there was no signi®cant difference between the incidences of dizziness and asthenia in patients with or without orthostatic changes (Table 2) . Patients were also strati®ed according to whether they had a 5 mmHg decrease or`5 mmHg decrease in sitting systolic blood pressure from baseline. Although not statistically signi®cant, dizziness was more common in those patients with`5 mmHg decrease in blood pressure than in those with 5 mmHg decrease. Asthenia was signi®cantly more common in patients with 5 mmHg decrease in systolic blood pressure. There was no signi®cant difference in the incidence of postural hypotension. These ®ndings suggest that orthostatic hypotension in men exposed to a 1 -adrenoceptor blockers is the only adverse event mediated by vascular effects. Dizziness and asthenia are potentially centrally mediated effects.
Comparative ef®cacy of the current agents
Although there are limited long-term data, comparison of placebo-controlled trials suggests that the current agents provide similar ef®cacy in terms of symptom relief. Data from these trials suggest that the current a 1 -adrenoceptor blockers improve¯ow rates by 10 ± 30%, and improve symptoms by 20 ± 40% ( Table 3 ).
Evidence that ef®cacy of a a 1 -adrenoceptor blockers in BPH has a centrally mediated component Clinical data suggest that the LUTS observed in patients with BOO may be due to neurogenic changes. Prostatic urethral anaesthesia with lidocaine and benoxinate relieves BOO symptoms in patients with BPH. 70 Also, therapies that do not relieve obstruction yet affect visceral afferent nerves can be as effective for LUTS and abolishing unstable bladder contractions as those which relieve obstruction. 71 Evidence of neurogenic changes following BOO have also been observed in animal studies. In a study involving rats with urethral ligation, 20% of animals continued to have persistent hyperactive voiding after urethral deligation, even though their bladder weights had normalized. 16 Increased levels of nerve growth factor (NGF) were also found in bladders and pelvic ganglia from these animals, compared with those from animals who improved after deligation (Steers and Chai, personal communication). This suggests that there are changes in the sensory limb of the micturition re¯ex pathway following obstruction and that in some animals this neuroplasticity persists. NGF levels are also increased in human obstructed bladders. 72 Another study found that prazosin reduces urinary frequency in ligated animals, even though these animals still had hypertrophic bladders. 73 Since this effect cannot be attributed to a relaxation of the urethral ligature in these animals, it could be potentially due to a central effect. Terazosin also reduces detrusor sphincter dyssynergia in patients with bladder neck contracture, possibly via a central effect. 74 63 
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et al (1998) 109 Enhanced spinal re¯exes are also present in patients with obstruction and storage symptoms, as demonstrated by the ice-water test that triggers a C ®bre, capsaicinsensitive spinal micturition re¯ex. This re¯ex, which is normally present only in the ®rst few months of life, reoccurs in patients with suprasacral spinal injuries or upper motor neurone disease. 75 , ± 78 Chai et al 79 found that the incidence of a positive ice water test was signi®cantly higher among patients with obstruction (12 of 17; 71%) than in those without obstruction (3 of 44; 7%), when patients with neurological disease were excluded from the analysis. In general, a positive ice water test was only observed in patients with LUTS if they also had BOO. The incidence of positive detrusor stability, however, was not statistically different between patients with or without BOO. These ®ndings suggest that a positive ice water test is associated with BOO and not LUTS. 79 If obstruction results in neurogenic changes, is the hyperactivity associated with LUTS and/or prostate growth related to sympathetic overactivity? Hypertension is an independent risk factor for LUTS, and increased sympathetic activity can lead to hypertension, although most cases of essential hypertension are not related to sympathetic overactivity per se. 80, 81 The SHR is a genetic model for hypertension. 82 Sympathetic overactivity in the SHR has been suggested on the basis of behavioural overactivity, 83 increased rates of sympathetic discharge in post-ganglionic nerves, 84 and increased noradrenaline (norepinephrine) content of vascular and other tissues. 85 Increased NGF levels are also observed in the spleen, the sciatic nerve, and the mesenteric artery from young SHRs. 86 Interestingly, prostates from SHRs demonstrate prostatic hyperplasia, 87 and SHRs exhibit urinary frequency and unstable bladder contractions. 88 In secondgeneration (F1) rats resulting from cross-breeding between SHR and their genetic counterparts Wistar ± Kyoto (WKY), blood pressure was found to correlate with urinary frequency. 89 SHRs exhibit increased urinary frequency compared with control rats, independent of age and bladder size, 90 together with non-micturition contractions and reduced sensory volume/pressure thresholds. 91 Catecholaminē uorescent staining of bladders from SHRs demonstrates that they have increased noradrenergic innervation compared with their genetic controls (WKY). 88 This is supported by the increased noradrenaline tissue content observed in bladders and prostates from SHRs compared with WKY controls. 92 Elevated levels of NGF are also found in bladders of SHRs. 90 Elevated NGF during development would be expected to lead to increased adrenergic and sensory innervation.
Intrathecal doxazosin reduces detrusor hyperactivity in SHRs, while peripherally administered doxazosin has no effect. 91 Both doxazosin and the adrenergic neurone blocker guanethidine increased the threshold volume in SHRs compared with WKY controls, and thus increased the sensory threshold for the micturition re¯ex in these animals. Centrally administered doxazosin was still effective after the sympathetic innervation had been destroyed with 6-hydroxydopamine, suggesting that efferent adrenergic nerves are not mediating this effect. Thus by default, visceral afferents may be involved in this overactivity (unpublished data).
Thus, although a 1 -adrenoceptors are not as common in the CNS as a 2 -adrenoceptors, they may be involved in the mode of action of a 1 -adrenoceptor blockers in the treatment of BPH. Although the mode of action of a 1 -adrenoceptor blockers in the treatment of BPH cannot be inferred from animal data, these data do raise questions concerning their mode of action. Although voiding symptoms of BPH are probably due to a peripheral effect, the storage symptoms may be due to changes in the afferent neurones within the CNS, following bladder obstruction or in¯am-mation. Spinal cord injuries have been shown to result in changes within the sacral spinal cord, 93 while in¯amma-tory changes can change proto-oncogenes and receptor regulation for transmitters such as glutamate. 94 Of the currently available a 1 -adrenoceptor blockers, doxazosin, terazosin, prazosin and tamsulosin appear to penetrate into the CNS. However, alfuzosin is thought to not enter the CNS and yet is effective in BPH. 95 A comparison of ef®cacy for relief of storage symptoms (irritative, LUTS) based on CNS penetration would be of interest in this regard. Ef®cacy has usually been determined from a composite scoring of symptom relief. Thus, if¯ow rates and voiding symptoms comprise a major portion of the outcome analysis, subtle differences between agents could be missed.
Future directions a a 1 -adrenoceptor selectivity
It is dif®cult to predict whether subtype selective a 1 -adrenoceptor blockers can provide improved ef®cacy and tolerability without fully elucidating the pathophysiology of BPH and identifying which a 1 -adrenoceptor subtypes are involved. As ef®cacy and tolerability of a 1 -adrenoceptor blockers appear to have a centrally mediated component, an a 1 -adrenoceptor subtype probably cannot be preferentially targeted as treatment for BPH. Relief of storage symptoms appears to be mediated via a central action, and thus an a 1A -adrenoceptor selective agent would not be expected to provide improved symptom relief since the a 1D -adrenoceptor subtype is predominant in structures in the CNS involved with micturition. In addition, asthenia and dizziness may be due to a central rather than vascular effect. Since the same receptor subtype within the CNS may mediate these side effects and the relief of storage symptoms, subtype selective agents may not provide improved tolerability.
Randomized double-blind placebo controlled trials with antagonists that are selective for each of the three a 1 -adrenoceptor subtypes would be required to determine which subtypes are involved in relieving the symptoms of BPH and in mediating the side effects of the a 1 -adrenoceptor blockers. To date, there is no subtype-selective drug that has been shown in clinical studies to be superior to the non-subtype-selective antagonists.
Alternative strategies
Combining the current a 1 -adrenoceptor blockers with other agents might also provide improved symptom relief. Traditionally muscarinic receptor antagonists have a a 1 -Adrenoceptor selectivity in BPH treatment R Kirby et al been contraindicted in patients with BPH due to fears of urinary retention. However, this dogma has been questioned recently and there are now ongoing studies in which a 1 -adrenoceptor blockers are being combined with muscarinic receptor antagonists. Since patients with BPH have detrusor instability, this combination might be bene®cial.
There is evidence that a 1 -adrenoceptor antagonists promote apoptosis of prostatic smooth muscle cells by removing the trophic in¯uence of noradrenaline. 96 Thus, a 1 -adrenoceptor antagonists that speci®cally promote apoptosis might be of interest, as might agents that promote apoptosis through other mechanisms.
A tyrosine kinase A antagonist, which inhibits NGF, is currently being developed for prostate cancer. This agent might also be bene®cial in BPH, since NGF has been implicated in the growth of the prostate 97, 98 and in changing the sensory and sympathetic nerves following obstruction. It would be interesting to analyse the symptom scores in patients receiving this agent.
The nitrosylated a-adrenoceptor antagonists, currently in development, act as both nitric oxide donors and a 1 -adrenoceptor antagonists. 99 Thus, these agents may have a role in the treatment of BPH, if nitric oxide (NO) is involved in the control of afferent nerves in the prostate or the lower urinary tract.
In the human prostate, there is dense nitrergic innervation of the ®bromuscular stroma, glandular epithelium, and blood vessels; particularly secretory cells, which are surrounded by a dense network of NOS-containing nerve terminals. 100 ± 103 In BPH, this nitrergic innervation is reduced. 101 In pharmacological studies, nitric oxide and electrical stimulation of nerves relaxed noradrenaline-contracted preparations of canine and human prostatic smooth muscle, while inhibition of NO synthesis abolished the electrically induced relaxation of smooth muscle. 102 ± 104 These ®ndings suggest that NO can regulate prostatic smooth muscle tone. However, NO may have effects not only on stromal smooth muscle, but also on secretory cells, and on vessels. Theoretically, lack of NO may lower the threshold for afferent ®ring leading to bladder instability and symptoms associated with BPH. However, there is so far no clinical evidence showing that this may be the case.
Endothelins, which can increase the contractileresponse to noradrenaline, are abundant in the prostate, 105, 106 and it may be speculated whether or not endothelin antagonists can be effective in BPH. Also, drugs such as capsaicin that inhibit sensory nerve ®bres might be useful. Preventative therapies for BPH may be possible once the pathophysiology of BPH has been more fully elucidated. 
